Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study on Diurnal Variation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~PKU PARTICIPANTS (ARM 1):~* Subject has a confirmed diagnosis of PKU with hyperphenylalaninemia documented by a fasting Phenylalanine level of at least 360 umol/L (6 mg/dL)~* Patient is at least 4 years old (there is no upper age limit for this study)~* Willing and able to provide written authorization or, if under the age of 18 years, provide written assent (if required) and written patient authorization by a parent or legal guardian~* Willing to undergo study related procedures including commencing Kuvan treatment for patient not currently on treatment; temporary discontinuation of Kuvan for patient on treatment; and completing the 24-Hour Blood Assessment~* Authorized to provide personal health information~* Subjects should not be pregnant and willing to use appropriate birth control during the study~CONTROL GROUP (ARM 2):~* Healthy, non-PKU individuals. They will be age-sex matched to the PKU group. They may be a relative (ex: sibling) of a PKU participant, but they don't have to be a blood relation.~* Individual is at least 4 years old (there is no upper age limit)~* Willing and able to provide written consent or, if under the age of 18 years, provide written assent and written participant authorization by a parent or legal guardian~* Authorized to provide personal health information~Exclusion Criteria (BOTH ARMS):~* Subjects who do not meet all the inclusion criteria~* Age \< 4 years~* Concomitant medical problems or medications which at the discretion of the principal investigator would put participant at health risk or prevent them from completing study.~* If female, unwillingness to use birth control during the period of the study drug administration (this doesn't apply to Arm 2)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PKU Participants (Arm 1) (Type: EXPERIMENTAL): * Subjects will be administered Kuvan once daily.~* They will undergo several blood draws, including a 24-Hour Blood Assessment (at Study Visit #2 before the commencement of Kuvan), plasma Phe/Tyr draws (at Study Visits #3, 4, and 5), and another 24-Hour Blood Assessment (at Study Visit #6).
- Control Group (Arm 2) (Type: NO_INTERVENTION): * Subjects allocated into this group will be healthy, non-PKU individuals that may be a relative (ex: sibling) of a PKU participant, but they don't have to be a blood relation.~* These subjects will undergo a 24-Hour Blood Assessment (at Study Visit #2).

Based on this trial design, predict the completion outcome and termination type (if applicable).